Caris Life Sciences, an Irving, Texas-based provider of molecular science focused on fulfilling the promise of precision medicine through quality and innovation, raised $150m in funding.
The funding was provided in the form of senior secured debt and convertible notes from TPG Sixth Street Partners, a global credit investment platform with $25 billion in assets under management.
The company intends to use the funds to continue development of Next Generation Profiling™, expand the commercial organization, increase clinical and R&D laboratory capacity, enhance biopharmaceutical business development capabilities, pursue patent enforcement and other strategic corporate initiatives.
to analyze whole genome, whole transcriptome and the complete cancer proteome with mature clinical outcomes to deliver proprietary offerings for more precise treatment recommendations.
Led by David D. Halbert, Chairman and CEO, Caris Life Sciences is advancing a suite of molecular profiling offerings that assess DNA, RNA and proteins to reveal a molecular blueprint that allows physicians and cancer patients to make precise and personalized treatment decisions. The company is also advancing precision medicine with Next Generation Profiling™ that combines its innovative service offerings, Caris Molecular Intelligence® and ADAPT Biotargeting System™, with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides molecular solutions for patients, physicians, payers and biopharmaceutical organizations. Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets.
FinSMEs
01/10/2018